Figure 6
From: SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
Reduction of clonogenic growth of neoplastic MCs from two patients with MCL (MCL3 and MCL7; blue and green curves, respectively) and one patient with ASM (ASM18; red curve) as compared to two healthy donors (HDs; black and gray curves) in the presence of increasing doses of bortezomib (0.25–1 nm) (a), AZD1775+midostaurin combination (0.025–0.1 μm) (b), AZD1775 alone (0.025–0.1 μm) (c), midostaurin alone (0.025–0.1 μm) (d). All the clonogenic survival rates are expressed as mean±s.d. of counts from three independent experiments. (e) Comparison of LD50 values for the different strategies.
